Biocon nears full integration of biologics business after Mylan buyback

The Bengaluru-based company on 14 January said it raised $460 million via a QIP of shares to buy out Mylan Inc’s (Viatris) stake in its arm Biocon Biologics. Days later, it announced the acquisition ...
Seeking Alpha

Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited

PITTSBURGH, Dec. 6, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that it has entered into definitive agreements with Biocon Limited ("Biocon") for the sale of Viatris' equity stake ...
Morningstar

Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options

BRIDGEWATER, N.J. and BENGALURU, India, Oct. 16, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: ...
Devdiscourse

Biocon Q3 net profit surges over 5-fold to Rs 144 cr

Biocon on Thursday reported over five-fold jump in consolidated net profit to Rs 144 crore for the third quarter ended ...
Drug Store News

Biocon Biologics unveils 3 new oncology biosimilars

Biocon Biologics also announced it received FDA approval for the Yesfali PFS (the pre-filled syringe application), a vascular endothelial growth factor inhibitor used to treat several different types ...
Seeking Alpha

Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars

BENGALURU, India and BRIDGEWATER, N.J., Oct. 1, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: BIOCON) ...
Forbes

Indian Tycoon Kiran Mazumdar-Shaw’s Biocon Buyout Deal Values Biologics Unit At $5.5 Billion

I write about Asia's richest, fast-growing businesses, and startups. Biocon—controlled by Indian pharmaceutical billionaire Kiran Mazumdar-Shaw—is buying the rest of privately held subsidiary Biocon ...
Los Angeles Magazine

Biocon Biologics And Civica Bring Lower-Cost Insulin Glargine To U.S. Patients

Members of the editorial and news staff of the Los Angeles magazine and the Engine Vision Media Network were not involved in the creation of this content. A new agreement between Biocon Biologics Ltd.
Nasdaq

Biocon Biologics Says FDA Approves Bosaya And Aukelso As Denosumab Biosimilars

(RTTNews) - Biocon Biologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd., announced Wednesday that the U.S. Food and Drug Administration (FDA) has approved Bosaya ...
Hosted on MSN

USD 5.5 billion deal: Biocon to merge biologics unit; to acquire stake held by Serum, Mylan

USD 5.5 billion deal: Biocon, an innovation-driven global biopharmaceuticals company, on Saturday, December 6 2025, announced a strategic move to fully integrate Biocon Biologics Limited (BBL) as a ...
Hosted on MSN

Biocon Biologics to sell Denosumab Biosimilars in Europe, rest of world

Biocon Biologics Ltd., a global biosimilars company and subsidiary of Biocon Ltd, has entered into a settlement agreement with Amgen Inc. This agreement allows Biocon Biologics to commercialise its ...